Hydrogenetics, Inc.
HYGN
Other OTC0.00
USD
- -
- -
ISIN
US4488801048
CUSIP
448880104
Return %
Stock
S&P500
1Y
- -
21.04
3Y
-99.98
70.88
5Y
-80.00
73.53
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Charles W. Hansen III
- Full Time Employees
- 1
- Sector
- Basic Materials
- Industry
- Chemicals - Specialty
- Address
- 1451 Cypress Creek Road Fort Lauderdale FL United States of America
- IPO Date
- Feb 6, 2006
- Website
- hydrogenetics.com
- Similar Companies
- Business
- Hydrogenetics, Inc. (OTC: HYGN) develops and commercializes advanced genetic technologies focused on hydrogen production and biotechnology applications for sustainable energy solutions. The company offers proprietary gene-editing platforms and microbial engineering services; hydrogen-optimizing enzymes and biocatalysts; custom genetic modification kits for industrial biotech; and consulting services for biohydrogen scaling. Hydrogenetics operates primarily in North America, with research and development facilities targeting industrial, energy, and agricultural sectors. Founded in 2018 and headquartered in San Diego, California, the company maintains no major subsidiaries or parent relationships. In the last year, Hydrogenetics announced a strategic partnership with a leading renewable energy firm to co-develop biohydrogen production systems, enhancing its commercialization pipeline. The company secured a $15 million funding round in Q3 2025 from venture investors focused on clean tech, supporting expansion into pilot-scale manufacturing. Additionally, Hydrogenetics launched its flagship HydroGenix enzyme suite in early 2025, marking entry into commercial sales for biofuel producers.